Cat. No.: HY-10005

Flavopiridol

(Synonyms: HMR-1275; Alvocidib; L86-8275)

54 Cited Publications

고객리뷰

Based on 54 publication(s) in Google Scholar

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.68%
CAS No.: 146426-40-6
화학식: C₂₁H₂₀ClNO₅
분자량:401.84

보관:

4°C, stored under nitrogen

* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

Flavopiridol Chemical Structure

CAS No.: 146426-40-6

사이즈

가격

재고

수량

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability 견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

대량구매 문의

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (54)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Bioz

Biological Activity

제품 설명

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

IC₅₀ & Target^[3]

CDK1/Cyc B1

30 nM (IC₅₀)

CDK2/Cyc E

170 nM (IC₅₀)

CDK4/Cyc D1

100 nM (IC₅₀)

MAP

19000 nM (IC₅₀)

PKC

14000 nM (IC₅₀)

EGFR

22000 nM (IC₅₀)

All CDK Isoforms :

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	0.023 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.029 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.031 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.064 μM Compound: Flavopiridol	Growth inhibition of human A2780 cells after 48 hrs by MTT assay Growth inhibition of human A2780 cells after 48 hrs by MTT assay	[PMID: 33581551]
A2780	IC₅₀	0.038 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.056 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.071 μM Compound: 1 (flavopiridol)	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay	[PMID: 15027863]
A2780	IC₅₀	0.078 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	15 μM Compound: 1 (flavopiridol)	Inhibition of A2780 cell clonogenic assay Inhibition of A2780 cell clonogenic assay	[PMID: 11063609]
A2780	IC₅₀	71 nM Compound: 1	Cytotoxic effect on human ovarian (A2780) cancer cell line Cytotoxic effect on human ovarian (A2780) cancer cell line	[PMID: 15125971]
A-431	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of A431 human squamous cell carcinoma cell proliferation Inhibition of A431 human squamous cell carcinoma cell proliferation	[PMID: 12190313]
A549	CC₅₀	>100 μM Compound: 11; L86-8275, HMR1275	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33539089]
A549	GI₅₀	0.14 μM Compound: FVP	Antiproliferative activity against human A549 cells after 3 days by SRB method Antiproliferative activity against human A549 cells after 3 days by SRB method	[PMID: 25914804]
A549	GI₅₀	0.145 μM Compound: Flavopiridol	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 33581551]
A549	IC₅₀	0.096 μM Compound: Flavopiridol	Inhibition of A549 human lung carcinoma cell proliferation Inhibition of A549 human lung carcinoma cell proliferation	[PMID: 12190313]
A549	IC₅₀	0.1 μM Compound: Flavopiridol	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
ABAE	IC₅₀	0.045 μM Compound: Flavopiridol	Inhibition of ABAE human fibroblast cell proliferation Inhibition of ABAE human fibroblast cell proliferation	[PMID: 12190313]
BJ	EC₅₀	>86.2069 μM Compound: 4	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Caco-2	IC₅₀	0.086 μM Compound: Flavopiridol	Inhibition of CACO-2 human colon carcinoma cell proliferation Inhibition of CACO-2 human colon carcinoma cell proliferation	[PMID: 12190313]
CCRF-CEM	IC₅₀	0.052 μM Compound: Flavopiridol	Inhibition of CCRF-CEM human leukemia cell proliferation Inhibition of CCRF-CEM human leukemia cell proliferation	[PMID: 12190313]
CNE-2	IC₅₀	0.12 μM Compound: Flavopiridol	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
COLO 205	EC₅₀	>20 μM Compound: Chemical Probe: Flavopiridol	Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry	[PMID: 24919854]
CWR22R	IC₅₀	0.24 μM Compound: FP	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672930]
DU-145	GI₅₀	0.15 μM Compound: FVP	Antiproliferative activity against human DU145 cells after 3 days by SRB method Antiproliferative activity against human DU145 cells after 3 days by SRB method	[PMID: 25914804]
HCT-116	EC₅₀	0.034 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs	[PMID: 27326333]
HCT-116	GI₅₀	0.056 μM Compound: Flavopiridol	Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay	[PMID: 33581551]
HCT-116	IC₅₀	0.017 μM Compound: Flavopiridol	Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.018 μM Compound: Flavopiridol	Inhibition of HCT116 human colon carcinoma cell proliferation Inhibition of HCT116 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.021 μM Compound: Flavopiridol	Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.03 μM Compound: Flavopiridol	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HCT-116	IC₅₀	13 μM Compound: 1 (flavopiridol)	Inhibition of HCT116 cell clonogenic assay Inhibition of HCT116 cell clonogenic assay	[PMID: 11063609]
HCT-116	IC₅₀	20 nM Compound: Alvocidib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
HeLa	CC₅₀	0.12 μM Compound: 8; Alvocidib	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 27171036]
HeLa	GI₅₀	0.043 μM Compound: Flavopiridol	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 33581551]
HeLa	IC₅₀	0.15 μM Compound: Flavopiridol	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HepG2	EC₅₀	0.1464 μM Compound: 4	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
HepG2	IC₅₀	0.56 μM Compound: Flavopiridol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HL-60	IC₅₀	0.046 μM Compound: Flavopiridol	Inhibition of HL60 human leukemia cell proliferation Inhibition of HL60 human leukemia cell proliferation	[PMID: 12190313]
HMEC-1	GI₅₀	0.061 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.062 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.066 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay	[PMID: 23301767]
HS27	IC₅₀	0.051 μM Compound: Flavopiridol	Inhibition of Hs 27 human fibroblast cell proliferation Inhibition of Hs 27 human fibroblast cell proliferation	[PMID: 12190313]
HT-29	GI₅₀	0.131 μM Compound: Flavopiridol	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 33581551]
K562	IC₅₀	0.13 μM Compound: Flavopiridol	Inhibition of K562 human leukemia cell proliferation Inhibition of K562 human leukemia cell proliferation	[PMID: 12190313]
K562	IC₅₀	125 nM Compound: Alvocidib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
KB	GI₅₀	0.16 μM Compound: FVP	Antiproliferative activity against human KB cells after 3 days by SRB method Antiproliferative activity against human KB cells after 3 days by SRB method	[PMID: 25914804]
KOPN-8	EC₅₀	0.1926 μM Compound: 4	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
LNCaP	IC₅₀	0.016 μM Compound: Flavopiridol	Inhibition of LNCaP human prostate carcinoma cell proliferation Inhibition of LNCaP human prostate carcinoma cell proliferation	[PMID: 12190313]
LS174T	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of LS174T human colon carcinoma cell proliferation Inhibition of LS174T human colon carcinoma cell proliferation	[PMID: 12190313]
LX-1	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of LX-1 human lung carcinoma proliferation Inhibition of LX-1 human lung carcinoma proliferation	[PMID: 12190313]
M109	IC₅₀	0.08 μM Compound: Flavopiridol	Inhibition of M109 mouse lung carcinoma cell proliferation Inhibition of M109 mouse lung carcinoma cell proliferation	[PMID: 12190313]
MCF7	GI₅₀	0.092 μM Compound: Flavopiridol	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 33581551]
MCF7	IC₅₀	0.026 μM Compound: 1	Antiproliferative activity against MCF7 cells Antiproliferative activity against MCF7 cells	[PMID: 17123821]
MCF7	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of MCF-7 human breast carcinoma cell proliferation Inhibition of MCF-7 human breast carcinoma cell proliferation	[PMID: 12190313]
MCF7	IC₅₀	0.5 μM Compound: 1	Inhibition of MCF-7 tumor cell proliferation Inhibition of MCF-7 tumor cell proliferation	[PMID: 10843211]
MCF7	IC₅₀	0.71 μM Compound: Flavopiridol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-231	IC₅₀	0.06 μM Compound: Flavopiridol	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-468	GI₅₀	0.096 μM Compound: Flavopiridol	Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	GI₅₀	0.078 μM Compound: Flavopiridol	Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	IC₅₀	320 nM Compound: Alvocidib	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
MIA PaCa-2	IC₅₀	36 μM Compound: 1 (flavopiridol)	Inhibition of Mia PaCa-2 cell clonogenic assay Inhibition of Mia PaCa-2 cell clonogenic assay	[PMID: 11063609]
MIP	IC₅₀	0.12 μM Compound: Flavopiridol	Inhibition of MIP human colon carcinoma cell line Inhibition of MIP human colon carcinoma cell line	[PMID: 12190313]
MLF	IC₅₀	0.072 μM Compound: Flavopiridol	Inhibition of MLF mouse lung fibroblast cell proliferation Inhibition of MLF mouse lung fibroblast cell proliferation	[PMID: 12190313]
MOLM-13	IC₅₀	0.07 μM Compound: Flavopiridol	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MRC5	GI₅₀	0.028 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.039 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.049 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 23301767]
MT4	EC₅₀	0.015 μM Compound: FVP	Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay	[PMID: 25914804]
MT4	IC₅₀	0.067 μM Compound: FVP	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 25914804]
MV4-11	IC₅₀	0.079 μM Compound: 1	Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay	[PMID: 34415148]
NCI-N87	IC₅₀	111 nM Compound: Alvocidib	Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
Oocyte	IC₅₀	0.2 μM Compound: Flavopiridol	Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes	[PMID: 12593668]
Oocyte	IC₅₀	0.4 μM Compound: Flavopiridol (table 2 Page 6846)	Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes	[PMID: 16250643]
OVCAR-3	IC₅₀	0.054 μM Compound: Flavopiridol	Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation	[PMID: 12190313]
PC-3	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of PC3 human prostate carcinoma cell proliferation Inhibition of PC3 human prostate carcinoma cell proliferation	[PMID: 12190313]
PC-3	IC₅₀	10 μM Compound: 1 (flavopiridol)	Inhibition of PC3 cell clonogenic assay Inhibition of PC3 cell clonogenic assay	[PMID: 11063609]
PC-3	IC₅₀	110 nM Compound: Alvocidib	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
RPMI-8226	IC₅₀	140 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay	[PMID: 19169685]
RPMI-8226	IC₅₀	394 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay	[PMID: 19169685]
SEM	EC₅₀	0.2043 μM Compound: 4	Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Sf21	IC₅₀	395 nM Compound: 8; Alvocidib	Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate	[PMID: 27171036]
Sf9	IC₅₀	0.012 μM Compound: flavopiridol	Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells	[PMID: 17904366]
Sf9	IC₅₀	0.13 μM Compound: FVP	Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography	[PMID: 25914804]
Sf9	IC₅₀	2.5 nM Compound: 8; Alvocidib	Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis	[PMID: 27171036]
SK-BR-3	IC₅₀	0.077 μM Compound: Flavopiridol	Inhibition of SKBR-3 human breast carcinoma cell proliferation Inhibition of SKBR-3 human breast carcinoma cell proliferation	[PMID: 12190313]
SK-BR-3	IC₅₀	75 nM Compound: Alvocidib	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SK-OV-3	IC₅₀	0.22 μM Compound: Alvocidib	Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SUP-B15	EC₅₀	>86.2069 μM Compound: 4	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
T-cell	IC₅₀	20 nM Compound: 1; L868275	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 35485642]
T-cell	IC₅₀	6 nM Compound: Flavopiridol	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 19169685]
UoC-B1	EC₅₀	0.2084 μM Compound: 4	Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]

In Vitro

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases^[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol^[2].
Flavopiridol (Alvocidib) also inhibits cyclin E1 and induces apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 146426-40-6
Appearance Solid
분자량 401.84
화학식 C₂₁H₂₀ClNO₅
Color Light yellow to yellow
SMILES

O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O
Synonyms

HMR-1275; Alvocidib; L86-8275
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, stored under nitrogen

* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

Publications (54)

All Cell Imaging/StainingCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCFlow CytometryWB

Sort by:

Journal Impact Factor

Nature

Mapping and engineering RNA-driven architecture of the multiphase nucleolus. [Abstract]

2025 Aug;644(8076):557-566. PMID: 40604277

Flavopiridol purchased from MedChemExpress. Usage Cited in: Nature. 2025 Aug;644(8076):557-566. [Abstract]

Nucleolar morphology (IF for RPA194, FBL, and NPM1 for FC, DFC and GC) in DMSO (-FVP) and after 30-90 min of 2 μM FVP (Flavopiridol) treatment.
Nature

Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. [Abstract]

2024 Apr;628(8007):408-415. PMID: 38480883

Flavopiridol purchased from MedChemExpress. Usage Cited in: Nature. 2024 Apr;628(8007):408-415. [Abstract]

Immunoblotting showing CDK9, Ser2P and β-Actin protein levels in macrophages treated with either DMSO or Flavopiridol (10 μM) for 30 min. n = 3 independent experiments.
Cell

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. [Abstract]

2021 Apr 15;184(8):2167-2182.e22. PMID: 33811809
Cancer Discov

Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. [Abstract]

2021 Oct 6;candisc.1848.2020. PMID: 34615656
Nat Biomed Eng

Inhibition of LARP4-mediated quiescence exit of naive CD4+ T cells ameliorates autoimmune and allergic diseases. [Abstract]

2025 Oct 16. PMID: 41102557
Nat Commun

CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma. [Abstract]

2024 Dec 5;15(1):10594. PMID: 39632829
Acta Pharm Sin B

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. [Abstract]

2022 Jul;12(7):3139-3155. PMID: 35865097

Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 0-1 μg/mL; 24 h). MTT assay-derived curves of PF, Flav, PF + Flav and PNM in 4T1 cells after 24 h of treatment.

Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Schedule of establishment of the 4T1 tumor-bearing mouse model and different treatments. Average tumor growth curves of the mice treated with PBS, PF, Flav, PF + Flav and PNM.

Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Representative pictures of HE staining and Ki-67 staining in tumor sections of different groups.

Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Representative flow cytometric plots of CD8⁺ T cells in tumors.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Biomaterials

Repair of spinal cord injury by inhibition of astrocyte growth and inflammatory factor synthesis through local delivery of flavopiridol in PLGA nanoparticles. [Abstract]

2014 Aug;35(24):6585-94. PMID: 24811262
Plant Cell

ZmSSRP1 facilitates the progression of RNA polymerase II and is essential for kernel development in maize. [Abstract]

2025 Apr 1:koaf071. PMID: 40166832
Clin Cancer Res

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]

2020 Apr 15;26(8):2011-2021. PMID: 31937620
Int J Biol Sci

DDX24 Mutation Alters NPM1 Phase Behavior and Disrupts Nucleolar Homeostasis in Vascular Malformations. [Abstract]

2023 Aug 6;19(13):4123-4138. PMID: 37705750
Proc Natl Acad Sci U S A

Cell division in the shoot apical meristem is a trigger for miR156 decline and vegetative phase transition in Arabidopsis. [Abstract]

2021 Nov 16;118(46):e2115667118. PMID: 34750273
Cell Commun Signal

Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. [Abstract]

2022 Sep 5;20(1):96. PMID: 36058938
Int J Biol Macromol

Trained immunity driven by Enterococcus faecalis ribosomal protein S11 enhances antigen presentation and boosts influenza vaccine efficacy via nanoparticle delivery. [Abstract]

2025 May 15:144179. PMID: 40381785
EMBO Mol Med

Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]

2025 Nov 26. PMID: 41299101
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Cell Chem Biol

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. [Abstract]

2019 Aug 15;26(8):1067-1080.e8. PMID: 31178407
Cell Chem Biol

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. [Abstract]

2018 Feb 15;25(2):135-142.e5. PMID: 29276047
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Cell Rep

Mechanism of Virus Attenuation by Codon Pair Deoptimization. [Abstract]

2020 Apr 28;31(4):107586. PMID: 32348767
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
EMBO Rep

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. [Abstract]

2022 Jun 7;23(6):e53932. PMID: 35403787
Cell Mol Life Sci

TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. [Abstract]

2021 Feb;78(3):949-962. PMID: 32440711
Am J Physiol Cell Physiol

Thrombopoietin Mitigates Neuronal Death by Enhancing Mitophagy and Suppressing NLRP3 Inflammasome Activation Under Oxygen-Glucose Deprivation Conditions. [Abstract]

2025 Aug 20. PMID: 40833847
Molecules

Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes. [Abstract]

2023 Mar 4;28(5):2368. PMID: 36903615
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
ACS Omega

Total Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290. [Abstract]

2025 Aug 16;10(33):38240-38254. PMID: 40893326
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
Sci Rep

Flavopiridol induces cell cycle arrest and apoptosis by interfering with CDK1 signaling pathway in human ovarian granulosa cells. [Abstract]

2024 Oct 31;14(1):26239. PMID: 39482384
Sci Rep

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. [Abstract]

2021 Mar 8;11(1):5374. PMID: 33686114
Sci Rep

Evidence for transcriptional interference in a dual-luciferase reporter system. [Abstract]

2015 Dec 1;5:17675. PMID: 26620302
J Virol

2026 May 11.
ACS Chem Biol

A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]

2017 May 19;12(5):1245-1256. PMID: 28263556
PLoS Genet

Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos. [Abstract]

2024 Jun 3;20(6):e1011308. PMID: 38829886
Int J Med Sci

NCAPH Promotes the Proliferation of Prostate Cancer Cells Via Modulating the E2F1 Mediated PI3K/AKT/mTOR Axis. [Abstract]

2025 Jan 27;22(4):940-954. PMID: 39991770
Toxicol Lett

Flavopiridol inhibits oocyte maturation, reduces oocyte quality and blocks cumulus cell function. [Abstract]

2024 Sep 12:S0378-4274(24)02025-3. PMID: 39276810
Biochem Biophys Res Commun

CDK9 modulates circadian clock by attenuating REV-ERBα activity. [Abstract]

2019 Jun 11;513(4):967-973. PMID: 31005255
Turk Neurosurg

Intrathecal Administration of Flavopiridol Promotes Regeneration in Experimental Model of Spinal Cord Injury. [Abstract]

2016;26(6):922-929. PMID: 27476919
Albert Einstein College of Medicine

2026.
bioRxiv

ATM promotes reversed fork processing during DNA interstrand cross-link repair. [Abstract]

2025 Oct 9:2025.10.08.680157. PMID: 41279244
bioRxiv

2025 Aug 19.
University of Washington

2025.
bioRxiv

Mapping and engineering RNA-controlled architecture of the multiphase nucleolus. [Abstract]

2024 Sep 29:2024.09.28.615444. PMID: 39386460
bioRxiv

2024 July 27.
Research Square Preprint

2024 May 2.
Research Square Preprint

2024 Apr 2.
bioRxiv

2024 Mar 17.
bioRxiv

2023 Sep 7.
Purdue University

2022.
The University of Chicago

2022 Aug.
Research Square Preprint

2022 Jan.
Free University of Berlin

2021 Mar.
University of North Carolina at Chapel Hill

2020 Jun.

용액&용해도

In Vitro:

DMSO : 33.33 mg/mL (82.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4886 mL

12.4428 mL

24.8855 mL

5 mM

0.4977 mL

2.4886 mL

4.9771 mL

10 mM

0.2489 mL

1.2443 mL

2.4886 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (stored under nitrogen). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/NSC-187208 samples, NSC-187208 is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. [Content Brief]

[2]. Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. [Content Brief]

[3]. Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. [Content Brief]

[4]. Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17(1):85. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4886 mL	12.4428 mL	24.8855 mL	62.2138 mL
	5 mM	0.4977 mL	2.4886 mL	4.9771 mL	12.4428 mL
	10 mM	0.2489 mL	1.2443 mL	2.4886 mL	6.2214 mL
	15 mM	0.1659 mL	0.8295 mL	1.6590 mL	4.1476 mL
	20 mM	0.1244 mL	0.6221 mL	1.2443 mL	3.1107 mL
	25 mM	0.0995 mL	0.4977 mL	0.9954 mL	2.4886 mL
	30 mM	0.0830 mL	0.4148 mL	0.8295 mL	2.0738 mL
	40 mM	0.0622 mL	0.3111 mL	0.6221 mL	1.5553 mL
	50 mM	0.0498 mL	0.2489 mL	0.4977 mL	1.2443 mL
	60 mM	0.0415 mL	0.2074 mL	0.4148 mL	1.0369 mL
	80 mM	0.0311 mL	0.1555 mL	0.3111 mL	0.7777 mL

Keywords

Flavopiridol

54 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Flavopiridol

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Flavopiridol

All CDK Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (54)

용액&용해도

Protocol

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Flavopiridol Related Classifications

Cat. No.: HY-10005